KR100312638B1 - Method for manufacturing high purity hyaluronic acid - Google Patents
Method for manufacturing high purity hyaluronic acid Download PDFInfo
- Publication number
- KR100312638B1 KR100312638B1 KR1019940022918A KR19940022918A KR100312638B1 KR 100312638 B1 KR100312638 B1 KR 100312638B1 KR 1019940022918 A KR1019940022918 A KR 1019940022918A KR 19940022918 A KR19940022918 A KR 19940022918A KR 100312638 B1 KR100312638 B1 KR 100312638B1
- Authority
- KR
- South Korea
- Prior art keywords
- hyaluronic acid
- resin
- nucleic acid
- activated carbon
- filtration
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Materials Engineering (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
[발명의 명칭][Name of invention]
고순도 히알우론산의 제조방법Method for producing high purity hyaluronic acid
[발명의 상세한 설명]Detailed description of the invention
본 발명은 미생물로부터 생산된 히알우론산(Hyaluronic acid)을 제조 및 정제하는 방법에 관한것이다.The present invention relates to a method for preparing and purifying hyaluronic acid produced from microorganisms.
히알우론산은 글루쿠론산(Glucuronic acid)과 N-아세틸 글루코사민(N-Acetyl glucosamine)이 1-3 결합과 1-4 결합으로 반복적으로 연결된 분자량이 5만-1300만인 고분자량의 직쇄상 다당류로 지금까지는 닭벼슬이나 소눈의 수정액, 탯줄같은 생체 조직으로 부터 추출하여 얻었으나, 이러한 방법은 많은 단점을 지니고 있다. 첫째, 생산수율이 낮고, 둘째, 콘드로이틴 설페이트(Chondroitin sulfate)와 글리코사미노 글리칸 설페이트(Glycosamino glycan sulfate)등의 불순물이 혼입되어 있고, 셋째, 제조 및 정제과정에서 비용이 많이 소요된다.Hyaluronic acid is a high molecular weight linear polysaccharide with a molecular weight of 50,000 to 13 million, in which glucuronic acid and N-acetyl glucosamine are repeatedly linked by 1-3 bonds and 1-4 bonds. Extracted from biological tissues such as chicken crust, cow's eye, and umbilical cord, but this method has many disadvantages. First, the production yield is low, and second, impurities such as chondroitin sulfate and glycosamino glycan sulfate are mixed. Third, the manufacturing and purification process is expensive.
이에 비하여 미생물에 의한 히알우론산의 생산방법은 스완(Swan)의 논문 Arch, Opthal., 88, 544(1970)에 의하면 첫째, 생산비가 저가이며, 둘째, 생산수율이 높고, 셋째, 생산된 히알우론산이 주사시 반응성이 낮고, 넷째, 높은 평균분자량을 갖고, 다섯째, 단백질 및 핵산과같은 불순물이 거의 존재하지 않는 등 여러가지 장점을 지녔다고 보고되었다.On the other hand, according to Swan's paper Arch, Opthal., 88, 544 (1970), the production method of hyaluronic acid by microorganisms is first, the production cost is low, second, the production yield is high, and third, the produced hyaluronic acid is injected. It has been reported to have various advantages such as low reactivity, fourth, high average molecular weight, and fifth, almost no impurities such as proteins and nucleic acids.
히알우론산은 눈의 초자액 및 포유류의 관절의 활액에서 발견되므로, 눈 및 관절의 병리상태를 치료하기위한 대용액으로서 인체주사를 필요로 하기 때문에 주사시 거부반응이 없어야 하므로 가능한한 고순도의 히알우론산을 얻는 것이 매우 중요하다. 의약품으로 사용하는 고순도 히알우론산 제제의 단백질 함량은 0.01% 이하, 핵산의 함량은 0.02% 이하 이여야 하는것으로 알려져 있다.Since hyaluronic acid is found in the vitreous fluid of the eye and the synovial fluid of the joints of mammals, it is necessary to inject the human body as a substitute for treating the pathology of the eyes and joints. Therefore, hyaluronic acid should be obtained as high as possible. It is very important. It is known that the protein content of the high purity hyaluronic acid preparation used as a pharmaceutical should be 0.01% or less and the nucleic acid content of 0.02% or less.
그러므로, 본 발명의 목적은 미생물로부터 생성된 히알우론산 생성물을, 단백질 함량이 0.01%이하, 핵산함량이 0.02%이하가 되도록, 정제하는 방법을 제공하는데 있다.Therefore, it is an object of the present invention to provide a method for purifying a hyaluronic acid product produced from a microorganism so that the protein content is 0.01% or less and the nucleic acid content is 0.02% or less.
한가지 바람직한 양태로서, 본 발명은 미생물로부터 생성된 히알우론산 함유 배양액을 에탄올 침전 및 적절한 수지들을 통하여 정제하여, 불순물(핵산, 단백질)이 없고, 미생물이 존재하지 않으며 의약용으로 사용할 수 있는 히알우론산을 제조하는 방법을 제공한다.In one preferred embodiment, the present invention purifies the hyaluronic acid-containing culture solution produced from microorganisms through ethanol precipitation and appropriate resins to produce hyaluronic acid, which is free of impurities (nucleic acid and protein), free of microorganisms and can be used for medical purposes. Provide a method.
더욱 바람직한 양태로서, 본 발명은 스트렙토리신의 생산능력이 없이 히알우론산만 생산하고, 비용혈성이며, 히알우로니다아제(히알우론산 분해효소)가 억제되고, 히알우론산의 생산능력이 증대되고, 배양시간이 짧고, 분자량이 비교적 큰 히알우론산을 생산하는 돌연변이 균주인 스트렙토코커스 에퀴 CH124(한국종균협회에 1994년 8월 22일자로 기탁번호 KFCC-10839로 기탁되었다)가 생성한 히알우론산을 활성탄과 규조토를 첨가하여 균체를 제거한 다음 두올라이트 A7 수지와 하이드록시아파타이트 수지를 이용하여 히알우론산 용액에 함유되어 있는 핵산과 단백질을 제거하여 고순도의 히알우론산을 제조하는 방법을 제공한다.In a more preferred embodiment, the present invention produces only hyaluronic acid without the production capacity of streptolysin, is non-hemolytic, inhibits hyaluronidase (hyaluronic acid degrading enzyme), increases the production capacity of hyaluronic acid, short incubation time, Hyaluronic acid produced by Streptococcus equine CH124 (muted strain KFCC-10839, deposited on August 22, 1994) with mutant strain producing hyaluronic acid with relatively high molecular weight was removed by adding activated carbon and diatomaceous earth. Next, a method of preparing high purity hyaluronic acid is provided by removing nucleic acids and proteins contained in a hyaluronic acid solution using a diolite A7 resin and a hydroxyapatite resin.
본 발명을 상세히 설명하면 다음과 같다. -70℃로 냉동 보관중인 변이주 스트렙토코커스 에퀴 CH124를 50㎖의 브래인 하트인퓨젼(Brain heart infusion) 배지가 함유된 250㎖ 플라스크 2개에 접종하고 회전 교반기(Rotary shaker)에서 14시간 배양하였다. 이 배양액 100㎖를 발효 배지가 2ℓ인 5ℓ 발효조에 접종하여 배양하였다. 이때 발효배지는 포도당 80g/ℓ, 효모 추출물 10g/ℓ, 대두박 추출액 35g/ℓ, 이인산칼륨 10g/ℓ, 일인산칼륨 10g/ℓ, 황산마그네슘 0.7g/ℓ, 황산암모늄 0.6g/ℓ, 황산망간 0.6g/ℓ등을 포함한다. 발효조건은 배양중 배지의 pH가 7.0이였고 배양 온도가 35-37℃, 통기량이 0.5-2.0vvm, 교반속도가 300-1,400rpm, 배양시간이 12-16시간이였다.The present invention is described in detail as follows. Variant strain Streptococcus equiqui CH124 frozen at −70 ° C. was inoculated into two 250 ml flasks containing 50 ml of Brain heart infusion medium and incubated for 14 hours in a rotary shaker. 100 ml of this culture was inoculated into a 5 L fermenter with a fermentation medium of 2 L and cultured. At this time, the fermentation medium is glucose 80g / l, yeast extract 10g / l, soybean meal extract 35g / l, potassium diphosphate 10g / l, potassium monophosphate 10g / l, magnesium sulfate 0.7g / l, ammonium sulfate 0.6g / l, sulfuric acid Manganese 0.6 g / l and the like. In the fermentation conditions, the pH of the culture medium was 7.0, the culture temperature was 35-37 ° C., the aeration amount was 0.5-2.0vvm, the stirring speed was 300-1,400 rpm, and the incubation time was 12-16 hours.
상기의 방법으로 배양하였을때, 배양후 균체 농도는 0D600nm=8.0-10.0, 히알우론산의 농도는 5-6g/ℓ정도였고, 평균 분자량은 300만-500만이였다.When cultured by the above method, the cell concentration after the culture was 0D 600nm = 8.0-10.0, the concentration of hyaluronic acid was about 5-6g / ℓ, the average molecular weight was 3 million to 5 million.
생산된 히알우론산 배양액의 균체제거 및 불순물 제거를 위하여 배양액에 염화 나트륨을 첨가하여 1.5M 염화 나트륨 용액이 되게하고 여기에 0.2-0.8%, 바람직하게는 0.4%의 활성탄(제일 탄소사)과 0.5-2.0%, 바람직하게는 2.0%의 규조토(삼손사, 200호)를 첨가하여 1시간이상 혼합하여 필터(Advantec사, NA-050)를 사용하여 필터프레스(Filter press)로 여과하였다. 이 여과액과 에탄올을 Y관을 이용하여 1:1.5 비율로 섞어 히알우론산을 침전 시켰다. 침전된 히알우론산을 제균된 질소가스로 건조시킨후 1.5M 염화나트륨용액에 용해시키고 0.1%의 활성탄과 0.5%의 규조토를 첨가한후 히알우론산이 완전히 용해되면 필터(NA-050)를 사용하여 여과시켰다. 이 여과액과 에탄올을 Y관을 이용하여 1:1.5비율로 섞어 히알우론산을 침전 시킨후, 침전된 히알우론산을 제균된 질소가스로 건조시켰다.Sodium chloride was added to the culture broth to obtain 1.5 M sodium chloride solution to remove the cells and remove the impurities of the hyaluronic acid culture, and 0.2-0.8%, preferably 0.4% of activated carbon (Cheil Carbon) and 0.5-2.0 %, Preferably 2.0% of diatomaceous earth (Samson Corporation, No. 200) was added and mixed for at least 1 hour, and filtered using a filter press (Filter press) using a filter (Advantec, NA-050). The filtrate and ethanol were mixed in a 1: 1.5 ratio using a Y tube to precipitate hyaluronic acid. The hyaluronic acid precipitated was dried with sterile nitrogen gas, dissolved in 1.5M sodium chloride solution, 0.1% activated carbon and 0.5% diatomaceous earth were added, and the hyaluronic acid was completely dissolved and filtered using a filter (NA-050). The filtrate and ethanol were mixed at a ratio of 1: 1.5 using a Y tube to precipitate hyaluronic acid, and the precipitated hyaluronic acid was dried with sterile nitrogen gas.
건조된 히알우론산을 수지작업을 위하여, 증류수에 녹이고 염화 나트륨을 첨가하여 전도도 40-50mS, pH4.0-8.0이 되게하였다. 이 용액을 두올라이트(Duolite) A7 (Diamond Shamrock사)수지를 통과시켰다. 수지 처리조건은 유속 2SV, pH 7.0, 히알우론산 농도 2-4g/ℓ, 처리량 7RV이내로 하였다. 수지 통과된 액을 1.5배의 에탄올에 처리하여 침전 시켰다. 침전된 히알우론산을 1-3g/ℓ 정도로 증류수에 녹인후, 하이드록시아파타이트(Hydroxyapatite, Bio-rad사)수지를 0.2% 첨가하여 2시간 반응시켰다. 용액중의 수지를 필터로 제거한후, 0.2㎛의 셀룰로오스 아세테이트 필터(Cellulose acetate filter, Sartorius사)를 사용하여 제균 여과하였다. 이 용액을 1M 염화나트륨용액으로 만든후, 1.5배의 에탄올용액에 첨가하여 침전 시킨후, 시약급 에탄올로 세척하여 염화나트륨을 제거하였다. 침전된 히알우론산을 제균된 질소가스로 건조시켰다.The dried hyaluronic acid was dissolved in distilled water for the resin work, and sodium chloride was added to have a conductivity of 40-50 mS and pH 4.0-8.0. This solution was passed through a Duolite A7 (Diamond Shamrock) resin. Resin treatment conditions were flow rate 2SV, pH 7.0, hyaluronic acid concentration 2-4g / ℓ, throughput was less than 7RV. The solution passed through the resin was treated with 1.5 times ethanol to precipitate. The precipitated hyaluronic acid was dissolved in distilled water at about 1-3g / L, and 0.2% of hydroxyapatite (Hydroxyapatite, Bio-rad) resin was added and reacted for 2 hours. The resin in the solution was removed by a filter, followed by sterilization filtration using a 0.2 µm cellulose acetate filter (Cellulose acetate filter, Sartorius). The solution was made into 1M sodium chloride solution, added to 1.5 times ethanol solution to precipitate, and washed with reagent-grade ethanol to remove sodium chloride. The precipitated hyaluronic acid was dried over sterile nitrogen gas.
스트렙토코커스 에퀴 CH124를 배양하여 발효액 1ℓ당 5-6g의 히알우론산을 얻었고, 상기의 정제공정을 통하여 1.5-2.5g의 최종히알우론산을 얻었다(정제수율 : 약 30-40%), 최종 히알우론산 제품의 분자량은 300만-400만 정도이였다.Streptococcus aquio CH124 was cultured to obtain 5-6 g of hyaluronic acid per liter of fermentation broth, and 1.5-2.5 g of final hyaluronic acid was obtained through the above purification process (purification yield: about 30-40%), and the molecular weight of the final hyaluronic acid product was It was about 3 million to 4 million.
미생물로 부터 생산된 히알우론산의 정제 과정을 요약하면 다음과 같다.Summary of the purification process of hyaluronic acid produced from microorganisms is as follows.
(1) 스트렙토코커스 에퀴 CH124 미생물 성장(1) Streptococcus Equi CH124 Microbial Growth
(2) 염화나트륨, 활성탄 및 규조토 첨가용해(2) dissolution of sodium chloride, activated carbon and diatomaceous earth
(3) 필터 여과(NA-050 필터 사용 필터 프레스 여과)(3) Filter filtration (filter press filtration using NA-050 filter)
(4) 히알우론산 용액의 에탄올 침전 및 건조(4) Ethanol Precipitation and Drying of Hyaluronic Acid Solution
(5) 염화나트륨, 활성탄 및 규조토 첨가 용해(5) dissolution of sodium chloride, activated carbon and diatomaceous earth addition
(6) 필터 여과 (NA-050 필터 사용)(6) Filter Filtration (using NA-050 filter)
(7) 히알우론산 용액의 에탄올 침전 및 건조(7) Ethanol Precipitation and Drying of Hyaluronic Acid Solution
(8) 염화나트륨 첨가하여 전도도 조절후 용해(8) Sodium chloride added to adjust conductivity
(9) 두올라이트 A7 수지 통과(9) passed through the zeolite A7 resin
(10) 히알우론산 용액의 에탄올 침전 및 건조(10) Ethanol Precipitation and Drying of Hyaluronic Acid Solution
(11) 하이드록시아파타이트 수지 첨가 반응(11) hydroxyapatite resin addition reaction
(12) 수지제거 및 제균여과(0.2㎛ 셀룰로오스 아세테이트 필터)(12) Resin removal and sterilization filtration (0.2 μm cellulose acetate filter)
(13) 히알우론산 용액의 에탄올 침전(13) Ethanol precipitation of hyaluronic acid solution
(14) 에탄올 세척 및 건조(14) ethanol washing and drying
본 발명의 다른 양태로서, 본 발명의 히알우론산 생성물은 히알우로니다아제-음성 또는 히알우로니다아제가 억제된 미생물로부터 제조하고, 단백질 및 핵산을 거의 함유하지 않으면서, 의약품으로 사용시 불필요한 오염 물질이라고 여겨지는 콘드로이틴 설페이트를 함유하지 않는다는 점에서 통상적으로 시판되는 히알우론산과 다르다.In another aspect of the invention, the hyaluronic acid product of the invention is prepared from microorganisms that are hyaluronidase-negative or hyaluronidase inhibited, and contain little protein or nucleic acid and are considered unnecessary contaminants when used in medicine. Is different from the commercially available hyaluronic acid in that it does not contain chondroitin sulfate.
분석방법은 히알우론산의 경우 빌터(Bilter)와 뮈어(Muir)의 논문 Anal. Biochem. 4., 330 (1962)에 의해 변형된 카바졸(Carbazol)법을 사용하였고, 균체 농도는 0D600nm에서 측정하였다. 단백질은 바이오 라드(Bio-rad)의 마이크로 분석법(Micro-assay)에의해 측정하였다. 이 방법은 25㎍/㎖ 이하의 낮은 단백질 농도까지 검출할 수 있다. 또한 핵산은 0D260nm에서 측정하였다. 분자량의 측정은 점도계에 의한 방법과 고속 액체 크로마토그라피(High Performance Liquid Chromatography)의 방법을 동시에 사용하였다. 점도에 의한 방법은 파스만(Fasman)의 논문 Crit. Rev. in Biochem., 8, 225 (1980)에서 제시된 [η]=0.036xMW0.76에 의거하였고, 고속 액체 크로마토그라피에 의한 법은 스웨덴의 파마시아(Pharmacia)사의 방법에 의거하였다.In the case of hyaluronic acid, the analytical method of Bilter and Muir, Anal. Biochem. 4. Carbazol modified by 330 (1962) was used, and the cell concentration was measured at 0D 600 nm . Proteins were measured by Bio-rad's Micro-assay. This method can detect up to low protein concentrations of 25 μg / ml or less. In addition, the nucleic acid was measured at 0D 260nm . The molecular weight was measured at the same time by a viscometer method and high performance liquid chromatography (High Performance Liquid Chromatography). The method by viscosity is described in Fasman's article Crit. Rev. [η] = 0.036xMW 0.76 presented in in Biochem., 8, 225 (1980), and the method by high performance liquid chromatography was based on the method of Pharmacia, Sweden.
[실시예 1]Example 1
여러가지 균체제거 방법을 실험하였다. 균체제거 방법중 운심분리 방법은 발효액을 원심 분리하여 균체를 제거하는 방법이다. 에탄올 침전법은 발효액을 에탄올로 침전시켜 균체를 제거하고 히알우론산을 얻은후 건조시켜 용해하는 방법이다. 여과법은 발효액을 여과(NA-050 필터사용)하여 균체를 제거한 것이다. 그 결과는 표 1에 기록되어있다. 균체제거 방법중에 여과법이 불순물인 핵산과 단백질이 가장 잘 제거되었다.Various cell removal methods were tested. The centrifugation method of the cell removal method is a method of removing the cells by centrifuging the fermentation broth. Ethanol precipitation is a method in which a fermentation broth is precipitated with ethanol to remove cells, hyaluronic acid is obtained, and then dried and dissolved. Filtration removes the cells by filtering the fermentation broth (using NA-050 filter). The results are recorded in Table 1. Among the cell removal methods, nucleic acids and proteins that were impurities were best removed.
[실시예 2]Example 2
불순물과 균체를 효과적으로 제거하기 위해 여과후 에탄올 침전법을 사용하였고, 이때 활성탄과 규조토를 첨가하여 히알우론산 회수율, 히알우론산 용액중 핵산과 단백질의 함량을 분석하였다. 1차 여과시 규조토의 농도를 1.0%로 하고 활성탄의 농도를 변화 시키면서 실험을 수행하였다. 표 2에서 알수있는 바와같이, 1차 여과시 활성탄 함량이 높을수록 핵산과 단백질은 잘제거 되었으나 히알우론산의 수율은 떨어졌다. 2차 여과시에는 활성탄 농도 0.1%, 규조토농도 1.0%로 여과하였다. 2차 여과시는 1차 여과의 영향으로 1차 여과시 활성탄 함량이 높을수록 핵산과 단백질은 잘제거 되었다.In order to effectively remove impurities and cells, ethanol precipitation was used after filtration, and activated carbon and diatomaceous earth were used to analyze hyaluronic acid recovery and the content of nucleic acid and protein in hyaluronic acid solution. In the first filtration, the concentration of diatomaceous earth was 1.0% and the experiment was performed while changing the concentration of activated carbon. As can be seen in Table 2, the higher the content of activated carbon during primary filtration, the better the removal of nucleic acids and proteins, but the yield of hyaluronic acid was lowered. In the second filtration, the resultant was filtered at 0.1% activated carbon concentration and 1.0% diatomaceous earth concentration. In the second filtration, the higher the amount of activated carbon in the first filtration, the better the nucleic acid and protein were removed.
*활성탄 농도 0.1%Activated carbon concentration 0.1%
1차 여과시 활성탄의 농도를 0.4%로 하고 규조토의 농도를 변화 시키면서 실험을 수행하였다. 표 3에서 알수있는 바와같이 1차 여과시 규조토 함량이 높을수록 핵산과 단백질은 잘제거되는 경향이 있었으나 큰차이는 없었다. 2차 여과시에는 활성탄 농도 0.1%, 규조토 농도 1.0%로 여과하였다. 2차 여과시에는 1차 여과의 영향으로 1차 여과시 규조토 함량이 높을수록 2차 여과시 핵산과 단백질이 잘제거 되었다.In the first filtration, the concentration of activated carbon was 0.4% and the experiment was performed while changing the concentration of diatomaceous earth. As can be seen in Table 3, the higher the diatomaceous earth content in the first filtration, the more likely the nucleic acid and protein were removed, but there was no significant difference. In the second filtration, the filtrate was filtered at 0.1% activated carbon and 1.0% diatomaceous earth. In the second filtration, the higher the diatomaceous earth content in the first filtration due to the effect of the first filtration, the better the nucleic acid and protein were removed during the second filtration.
*규조토 농도 1.0%Diatomaceous Earth Concentration 1.0%
[실시예 3]Example 3
히알우론산 제품에 함유된 불순물중 단백질은 에탄올 침전과정중에 거의 제거되었으나, 에탄올 침전을 여러번 반복하여도 핵산은 완전히 제거되지 않고 어느정도 포함되어 존재하였다. 그러므로, 히알우론산 용액중 핵산을 중점적으로 제거하기 위하여 두올라이트 A7 수지를 사용하여 실험을 수행하였다.Among the impurities contained in the hyaluronic acid product, the protein was almost removed during the ethanol precipitation process, but the nucleic acid was not completely removed but included to some extent even after repeated ethanol precipitation several times. Therefore, experiments were carried out using a duolite A7 resin to intensively remove the nucleic acid in the hyaluronic acid solution.
두올라이트 A7 수지의 최적화 실험중 전도도별 핵산 제거율을 측정한 결과 표 4와 같았다. 핵산 함량이 0.15%, 히알우론산의 농도가 3.0g/ℓ, pH가 7.0인 히알우론산 용액에 전도도를 변화시키면서 두올라이트 A7 수지를 통과 시켰다. 그 결과 전도도는 40mS 부근에서 핵산 제거율 65%로 핵산제거가 가장 잘 되었다.As a result of measuring the nucleic acid removal rate by conductivity during the optimization experiment of the diolite A7 resin, it was as shown in Table 4. The diaolite A7 resin was passed through the hyaluronic acid solution having a nucleic acid content of 0.15%, a concentration of hyaluronic acid at 3.0 g / L, and a pH of 7.0 with varying conductivity. As a result, the conductivity was the best in nucleic acid removal with 65% removal rate near 40mS.
핵산 함량이 0.15%, 히알우론산의 농도가 3.0g/ℓ, 전도도가 50mS인 히알우론산 용액에 pH를 변화시키면서 두올라이트 A7 수지를 통과시켰다. 그 결과 pH 7.0 부근에서 핵산 제거율 65%로 핵산제거가 가장 잘 되었다(표 5).The diaolite A7 resin was passed through a hyaluronic acid solution having a nucleic acid content of 0.15%, a concentration of hyaluronic acid at 3.0 g / L, and a conductivity of 50 mS with varying pH. As a result, nucleic acid removal was best with a nucleic acid removal rate of 65% near pH 7.0 (Table 5).
[실시예 4]Example 4
하이드록시아파타이트 수지 농도를 변화 시키면서 히알우론산 용액(핵산함량 0.05%, 히알우론산 농도 2.0g/ℓ, pH 7.0, 전도도 0.2mS)중에 첨가하여 30℃에서 2시간동안 반응시킨후 여과하여 수지를 제거한다음, 핵산 함량을 측정한 결과 표 6과 같았다. 하이드록시아파타이트 농도를 0.2% 이상, 바람직하게는 0.2내지 1.0% 첨가하면 핵산은 거의 제거되었다.While varying the hydroxyapatite resin concentration, it was added to a hyaluronic acid solution (nucleic acid content 0.05%, hyaluronic acid concentration 2.0g / l, pH 7.0, conductivity 0.2mS), reacted at 30 ° C for 2 hours, and then filtered to remove the resin. As a result of measuring the content, it was shown in Table 6. The addition of hydroxyapatite concentration of 0.2% or more, preferably 0.2 to 1.0%, almost eliminated the nucleic acid.
[실시예 5]Example 5
상기의 정제방법을 이용하여 정제 과정중에 히알우론산중에 포함되어 있는 핵산과 단백질의 함량을 조사한 결과 표 7과 같았다. 정제 단계중 두올라이트 A7 수지를 처리한 이후에는 단백질이 거의 제거 되었고, 하이드록시아파타이트 수지를 처리한 이후에는 불순물인 핵산과 단백질이 거의 제거되었다.As a result of examining the content of nucleic acid and protein contained in hyaluronic acid during the purification process using the above purification method was as shown in Table 7. After the treatment of the diolite A7 resin during the purification step, almost no protein was removed, and after treatment with the hydroxyapatite resin, impurities and nucleic acids and proteins were almost removed.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019940022918A KR100312638B1 (en) | 1994-09-09 | 1994-09-09 | Method for manufacturing high purity hyaluronic acid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019940022918A KR100312638B1 (en) | 1994-09-09 | 1994-09-09 | Method for manufacturing high purity hyaluronic acid |
Publications (2)
Publication Number | Publication Date |
---|---|
KR960010872A KR960010872A (en) | 1996-04-20 |
KR100312638B1 true KR100312638B1 (en) | 2001-12-28 |
Family
ID=37531251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019940022918A KR100312638B1 (en) | 1994-09-09 | 1994-09-09 | Method for manufacturing high purity hyaluronic acid |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100312638B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1766038A1 (en) * | 2004-06-16 | 2007-03-28 | T & Life System Co., Ltd. | Method for purifying hyaluronic acid using calcium salt and phosphate salt, or calcium |
KR101509139B1 (en) * | 2006-11-23 | 2015-04-08 | 주식회사 엘지생명과학 | Method for purifying hyaluronic acid |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6312293A (en) * | 1986-07-03 | 1988-01-19 | Kyowa Hakko Kogyo Co Ltd | Purification of hyaluronic acid |
KR880001763A (en) * | 1986-07-26 | 1988-04-26 | 정상영 | Epoxy Resin Composition for Semiconductor Encapsulation |
JPH04158796A (en) * | 1990-10-23 | 1992-06-01 | Chisso Corp | Production of aqueous solution of sodium hyaluronate |
US5316926A (en) * | 1983-11-25 | 1994-05-31 | Miles Inc. | Method for the microbiological production of non-antigenic hyaluronic acid |
KR960010852A (en) * | 1994-09-09 | 1996-04-20 | 김정순 | Streptococcus microorganisms produce hyaluronic acid |
-
1994
- 1994-09-09 KR KR1019940022918A patent/KR100312638B1/en not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5316926A (en) * | 1983-11-25 | 1994-05-31 | Miles Inc. | Method for the microbiological production of non-antigenic hyaluronic acid |
JPS6312293A (en) * | 1986-07-03 | 1988-01-19 | Kyowa Hakko Kogyo Co Ltd | Purification of hyaluronic acid |
KR880001763A (en) * | 1986-07-26 | 1988-04-26 | 정상영 | Epoxy Resin Composition for Semiconductor Encapsulation |
JPH04158796A (en) * | 1990-10-23 | 1992-06-01 | Chisso Corp | Production of aqueous solution of sodium hyaluronate |
KR960010852A (en) * | 1994-09-09 | 1996-04-20 | 김정순 | Streptococcus microorganisms produce hyaluronic acid |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1766038A1 (en) * | 2004-06-16 | 2007-03-28 | T & Life System Co., Ltd. | Method for purifying hyaluronic acid using calcium salt and phosphate salt, or calcium |
EP1766038A4 (en) * | 2004-06-16 | 2010-10-27 | T & Life System Co Ltd | Method for purifying hyaluronic acid using calcium salt and phosphate salt, or calcium |
KR101509139B1 (en) * | 2006-11-23 | 2015-04-08 | 주식회사 엘지생명과학 | Method for purifying hyaluronic acid |
Also Published As
Publication number | Publication date |
---|---|
KR960010872A (en) | 1996-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3081544B2 (en) | High molecular weight sodium hyaluronate composition | |
KR100236507B1 (en) | Gellan gum for non-brittle gels | |
JPH07504928A (en) | High-molecular glucuronic acid compounds, their production methods and uses, especially as gelling agents, viscosity-imparting agents, moisture-imparting agents, stabilizers, chelating agents, or flocculants | |
EP3730623A1 (en) | Small-molecule hyaluronic acid or salt thereof, and preparation method therefor | |
JPS6047694A (en) | Production of xanthomonus heteropolysaccharide and heteropolysaccharide prepared therefrom and use thereof | |
KR19980080116A (en) | Purification Method of Sodium Hyaluronate | |
SK10632001A3 (en) | Process for purifying high molecular weight hyaluronic acid | |
EP0307158B1 (en) | Process for the preparation of branched fructooligosaccharides | |
SU1429938A3 (en) | Method of treating culture fluid xanthomonas campestris containing polysaccharide | |
EP0621040B1 (en) | Method for reducing the number of contaminative live bacteria in xanthan gum | |
KR100312638B1 (en) | Method for manufacturing high purity hyaluronic acid | |
WO2013132506A1 (en) | Process for the purification of hyaluronic acid salts (ha) from fermentation broth | |
JPS6279790A (en) | Production of modified hyaluronic acid | |
CN105624067B (en) | Marine bacterium Pseudomonas sp SC127 and ulva sulfate rhamnosidase prepared by same | |
KR100250573B1 (en) | Hyaluronic acid | |
WO2021135597A1 (en) | Method for preparing heparinase i and tinzaparin sodium | |
DE69228761T2 (en) | METHOD FOR PRODUCING NEURAMINIDASE | |
CN1300311C (en) | Preparation method of chitin incision enzyme | |
CN113563488A (en) | Preparation method of pharmaceutical-grade micromolecular marine organism polysaccharide | |
JPS62289198A (en) | Novel process of producing hyaluronic acid | |
CN110066839A (en) | Culture medium for xanthan gum fermentation | |
JPH027631B2 (en) | ||
JPH0219393A (en) | N-acetylogalactosaminooligosaccahride and production thereof | |
KR100664582B1 (en) | Chitinase-producing trichoderma viride ????-?41 strain, chitinases purified therefrom and a method for producing ?-acetylglucosamine using the chitinases | |
JPH0144721B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120917 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20130829 Year of fee payment: 13 |
|
EXPY | Expiration of term |